NASDAQ:AGIO Agios Pharmaceuticals (AGIO) Stock Forecast, Price & News $27.03 +0.21 (+0.78%) (As of 06/7/2023 ET) Add Compare Share Share Today's Range$26.37▼$27.2150-Day Range$21.38▼$27.1252-Week Range$16.75▼$34.76Volume380,397 shsAverage Volume498,658 shsMarket Capitalization$1.50 billionP/E RatioN/ADividend YieldN/APrice Target$37.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Agios Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside36.7% Upside$37.00 Price TargetShort InterestBearish10.86% of Float Sold ShortDividend StrengthN/ASustainability-0.54Upright™ Environmental ScoreNews Sentiment0.05Based on 3 Articles This WeekInsider TradingSelling Shares$1.27 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($6.16) to ($5.19) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.88 out of 5 starsMedical Sector630th out of 982 stocksPharmaceutical Preparations Industry308th out of 480 stocks 3.4 Analyst's Opinion Consensus RatingAgios Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $37.00, Agios Pharmaceuticals has a forecasted upside of 36.7% from its current price of $27.06.Amount of Analyst CoverageAgios Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted10.86% of the float of Agios Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAgios Pharmaceuticals has a short interest ratio ("days to cover") of 11.3, which indicates bearish sentiment.Change versus previous monthShort interest in Agios Pharmaceuticals has recently increased by 1.58%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAgios Pharmaceuticals does not currently pay a dividend.Dividend GrowthAgios Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAgios Pharmaceuticals has received a 79.20% net impact score from Upright. Agios Pharmaceuticals seems to create the most significant positive value in categories "Jobs", "Physical diseases", and "Creating knowledge". The positive contribution in the "Physical diseases" impact category is driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Agios Pharmaceuticals is -0.54. Previous Next 1.7 News and Social Media Coverage News SentimentAgios Pharmaceuticals has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Agios Pharmaceuticals this week, compared to 3 articles on an average week.MarketBeat Follows3 people have added Agios Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Agios Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,266,695.00 in company stock.Percentage Held by InsidersOnly 4.24% of the stock of Agios Pharmaceuticals is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Agios Pharmaceuticals are expected to grow in the coming year, from ($6.16) to ($5.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Agios Pharmaceuticals is -6.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Agios Pharmaceuticals is -6.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAgios Pharmaceuticals has a P/B Ratio of 1.35. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Agios Pharmaceuticals (NASDAQ:AGIO) StockAgios Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.Read More Receive AGIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Agios Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AGIO Stock News HeadlinesJune 5, 2023 | finance.yahoo.comENSEM Announces the Promotion of Shengfang Jin, PhD to President & Chief Executive OfficerJune 5, 2023 | finance.yahoo.comAgios to Present at the Goldman Sachs Global Healthcare Conference on June 15, 2023June 7, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.May 30, 2023 | finance.yahoo.comAgios Pharmaceuticals (AGIO): Strong Industry, Solid Earnings Estimate RevisionsMay 25, 2023 | finance.yahoo.comDoes Agios Pharmaceuticals (AGIO) Have the Potential to Rally 34.83% as Wall Street Analysts Expect?May 25, 2023 | finance.yahoo.comAgios Appoints Catherine Owen to Board of DirectorsMay 24, 2023 | msn.comAgios Pharmaceuticals: Good Execution, A Good Deal Of Cash, Some HurdlesMay 19, 2023 | americanbankingnews.comAgios Pharmaceuticals (NASDAQ:AGIO) Coverage Initiated by Analysts at StockNews.comJune 7, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.May 17, 2023 | americanbankingnews.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Short Interest Up 6.3% in AprilMay 11, 2023 | finance.yahoo.comAgios to Present Clinical and Translational Data at European Hematology Association Annual CongressMay 10, 2023 | marketwatch.comCholangiocarcinoma Pipeline Market Hit Highest Growth Rate In 2031May 9, 2023 | msn.comWall Street Analysts Predict a 42.46% Upside in Agios Pharmaceuticals (AGIO): Here's What You Should KnowMay 9, 2023 | finance.yahoo.comWall Street Analysts Predict a 42.46% Upside in Agios Pharmaceuticals (AGIO): Here's What You Should KnowMay 8, 2023 | finance.yahoo.comAn Intrinsic Calculation For Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Suggests It's 48% UndervaluedMay 6, 2023 | americanbankingnews.comAgios Pharmaceuticals (NASDAQ:AGIO) Price Target Lowered to $34.00 at SVB SecuritiesMay 5, 2023 | finance.yahoo.comAgios (AGIO) Q1 Earnings Beat Estimates, Revenues Up Y/YMay 5, 2023 | finance.yahoo.comQ1 2023 Agios Pharmaceuticals Inc Earnings CallMay 4, 2023 | finanznachrichten.deAgios Pharmaceuticals, Inc.: Agios Reports Business Highlights and First Quarter 2023 Financial ResultsMay 4, 2023 | seekingalpha.comAgios Pharmaceuticals, Inc. (AGIO) Q1 2023 Earnings Call TranscriptMay 4, 2023 | seekingalpha.comAgios Pharmaceuticals, Inc. 2023 Q1 - Results - Earnings Call PresentationMay 4, 2023 | benzinga.comAgios Pharmaceuticals: Q1 Earnings InsightsMay 4, 2023 | finance.yahoo.comAgios Reports Business Highlights and First Quarter 2023 Financial ResultsMay 3, 2023 | marketwatch.comDihydrowhey Dehydrogenase (DHODH) Inhibitor Market Size 2023-2031 Industrial Overview by Absolute Reports | with [94 Pages]May 3, 2023 | americanbankingnews.comAgios Pharmaceuticals (NASDAQ:AGIO) Downgraded by StockNews.com to SellMay 2, 2023 | americanbankingnews.comAgios Pharmaceuticals (AGIO) to Release Quarterly Earnings on ThursdayApril 30, 2023 | americanbankingnews.comResearch Analysts Set Expectations for Agios Pharmaceuticals, Inc.'s Q1 2023 Earnings (NASDAQ:AGIO)See More Headlines AGIO Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AGIO Company Calendar Last Earnings5/04/2023Today6/07/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AGIO CUSIPN/A CIK1439222 Webwww.agios.com Phone(617) 649-8600FaxN/AEmployees390Year FoundedN/APrice Target and Rating Average Stock Price Forecast$37.00 High Stock Price Forecast$41.00 Low Stock Price Forecast$32.00 Forecasted Upside/Downside+38.2%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($3.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-231,800,000.00 Net Margins-1,146.58% Pretax Margin-1,146.58% Return on Equity-20.23% Return on Assets-18.08% Debt Debt-to-Equity RatioN/A Current Ratio17.55 Quick Ratio17.30 Sales & Book Value Annual Sales$14.24 million Price / Sales104.52 Cash FlowN/A Price / Cash FlowN/A Book Value$20.03 per share Price / Book1.34Miscellaneous Outstanding Shares55,580,000Free Float53,224,000Market Cap$1.49 billion OptionableOptionable Beta0.94 Key ExecutivesBrian M. GoffChief Executive Officer & DirectorCecilia JonesChief Financial OfficerClive PatienceChief Technical Operations OfficerSarah GheuensChief Medical Officer, Head-Research & DevelopmentCharlie NewmanChief Business OfficerKey CompetitorsDynavax TechnologiesNASDAQ:DVAX89bioNASDAQ:ETNBAurinia PharmaceuticalsNASDAQ:AUPHSyndax PharmaceuticalsNASDAQ:SNDXZentalis PharmaceuticalsNASDAQ:ZNTLView All CompetitorsInsiders & InstitutionsMacquarie Group Ltd.Bought 34,979 shares on 6/1/2023Ownership: 2.604%ProShare Advisors LLCSold 1,310 shares on 5/26/2023Ownership: 0.018%Ameriprise Financial Inc.Bought 67,705 shares on 5/22/2023Ownership: 0.550%JPMorgan Chase & Co.Sold 192,912 shares on 5/18/2023Ownership: 2.156%New York State Common Retirement FundSold 10,584 shares on 5/18/2023Ownership: 0.053%View All Insider TransactionsView All Institutional Transactions AGIO Stock - Frequently Asked Questions Should I buy or sell Agios Pharmaceuticals stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AGIO shares. View AGIO analyst ratings or view top-rated stocks. What is Agios Pharmaceuticals' stock price forecast for 2023? 4 brokerages have issued 12 month price targets for Agios Pharmaceuticals' shares. Their AGIO share price forecasts range from $32.00 to $41.00. On average, they predict the company's stock price to reach $37.00 in the next twelve months. This suggests a possible upside of 38.2% from the stock's current price. View analysts price targets for AGIO or view top-rated stocks among Wall Street analysts. How have AGIO shares performed in 2023? Agios Pharmaceuticals' stock was trading at $28.08 on January 1st, 2023. Since then, AGIO shares have decreased by 4.6% and is now trading at $26.78. View the best growth stocks for 2023 here. When is Agios Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our AGIO earnings forecast. How were Agios Pharmaceuticals' earnings last quarter? Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) announced its quarterly earnings data on Thursday, May, 4th. The biopharmaceutical company reported ($1.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.72) by $0.25. The biopharmaceutical company earned $5.61 million during the quarter, compared to the consensus estimate of $5.23 million. Agios Pharmaceuticals had a negative net margin of 1,146.58% and a negative trailing twelve-month return on equity of 20.23%. Agios Pharmaceuticals's revenue was up 574.2% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.74) earnings per share. What ETFs hold Agios Pharmaceuticals' stock? ETFs with the largest weight of Agios Pharmaceuticals (NASDAQ:AGIO) stock in their portfolio include First Trust NYSE Arca Biotechnology Index Fund (FBT), Virtus LifeSci Biotech Products ETF (BBP), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), WisdomTree BioRevolution Fund (WDNA), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco Nasdaq Future Gen 200 ETF (QQQS) and WisdomTree U.S. SmallCap Fund (EES). What is Jackie Fouse's approval rating as Agios Pharmaceuticals' CEO? 11 employees have rated Agios Pharmaceuticals Chief Executive Officer Jackie Fouse on Glassdoor.com. Jackie Fouse has an approval rating of 100% among the company's employees. This puts Jackie Fouse in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Agios Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), bluebird bio (BLUE), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), Tesla (TSLA) and Netflix (NFLX). What is Agios Pharmaceuticals' stock symbol? Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO." Who are Agios Pharmaceuticals' major shareholders? Agios Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (10.30%), BlackRock Inc. (8.67%), Armistice Capital LLC (6.23%), State Street Corp (5.51%), Farallon Capital Management LLC (3.77%) and Dimensional Fund Advisors LP (3.76%). Insiders that own company stock include Carman Alenson, Christopher Bowden, Darrin Miles, David P Schenkein and Theodore James Jr Washburn. View institutional ownership trends. How do I buy shares of Agios Pharmaceuticals? Shares of AGIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Agios Pharmaceuticals' stock price today? One share of AGIO stock can currently be purchased for approximately $26.78. How much money does Agios Pharmaceuticals make? Agios Pharmaceuticals (NASDAQ:AGIO) has a market capitalization of $1.49 billion and generates $14.24 million in revenue each year. The biopharmaceutical company earns $-231,800,000.00 in net income (profit) each year or ($3.97) on an earnings per share basis. How many employees does Agios Pharmaceuticals have? The company employs 390 workers across the globe. How can I contact Agios Pharmaceuticals? Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.agios.com. The biopharmaceutical company can be reached via phone at (617) 649-8600 or via email at investors@agios.com. This page (NASDAQ:AGIO) was last updated on 6/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agios Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.